Gapping up
In reaction to strong earnings/guidance:
- QD +4.3%
M&A news:
- AMID +30.3% (to be acquired by ArcLight Energy Partners for $5.25/unit in cash)
- WP +9.2% (to be acquired by Fidelity Nat'l Info (FIS) for approximately $43 bln in cash & stock)
- DB +5% (Deutsche Bank is reviewing strategic options and confirms discussions with Commerzbank)
- COTY +2.4% (Board unanimously recommends JAB Holding tender offer at a price of $11.65 per share in cash) .
Select China related names showing strength:
- YNDX +2.8%, WB +2.1%, MOMO +1.6%, TAL +1.5%, JD +1.3%, BABA +1.1%, .
Other news:
- PHAS +121.8% (announced that results from the Phase 1 clinical trial of PB2452 demonstrated that PB2452 provided immediate and sustained reversal of ticagrelor antiplatelet effects without report of drug-related serious adverse events)
- DERM +68% (positive results from a Phase 2b dose-ranging study of lebrikizumab)
- TORC +14.2% (positive end-of-Phase 2 meeting with FDA and planned initiation of global phase 3 program for RTB101)
- EW +7.9% (reports SAPIEN 3 Valve proves superior to surgery in Partner 3 Trial; results published in the New England Journal of Medicine)
- ARWR +4.6% (submits IND to FDA for adaptive Phase 2/3 trial of ARO-AAT for alpha-1 antitrypsin deficient liver disease)
- PLUG +4.1% (responds to Seeking Alpha article; says co has reported this in current liability as a transparent reflection of what the company is doing)
- CLVS +3.5% (to present data from post hoc exploratory analyses from the ARIEL3 Phase 3 clinical study of Rubraca)
- MAR +2.2% (will outline its plan to add between 275,000 and 295,000 rooms by 2021; sees FY21 EPS in line with estimates)
- CS +2% (in sympathy with DB) SAN +2% (in sympathy with DB)
- RBS +1.5% (in sympathy with DB)
- MNK +1.5% (appoints CFO)
Analyst comments:
- HIIQ +5.4% (upgraded to Buy at B. Riley FBR)
- OKTA +3.2% (upgraded to Buy from Neutral at Goldman)
- CARG +2% (resumed with a Buy from a Neutral at Goldman)
- ADNT +1.8% (upgraded to Sector Weight from Underweight at KeyBanc Capital Markets)
- DLPH +1.7% (upgraded to Sector Weight from Underweight at KeyBanc Capital Markets)
- ELAN +1.2% (upgraded to Buy from Neutral at BofA/Merrill)
- EXEL +1.1% (upgraded to Equal-Weight from Underweight at Morgan Stanley)
- DG +1% (upgraded to Overweight from Equal Weight at Barclays)